Skip to main content

Which Patients with Advanced Clear Cell Renal Cell Carcinoma Benefit Most from First-line Checkpoint Inhibitor Combination Regimens: A Meta-analysis of Individual Patient Data and Aggregate Data from Randomised Trials

In brief

First-line immunotherapy combinations halve the death hazard in poor-prognosis kidney cancer

Across four trials involving 3,320 patients, combination immunotherapy was linked to about half the death hazard in patients with poor-prognosis metastatic kidney cancer, but showed no significant benefit in those with a favourable prognosis. Benefit varied by prognosis, and PD-L1 expression also modified treatment effects; these subgroup findings do not establish which specific regimen is best for each patient.

Journal
European urology (Q1)
Published
16 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Anke Richters, Hans M Westgeest, Berna C Özdemir, Marinde J G Bond, Johanna A A Damen, Katja K H Aben, et al.
PMID
43039767
DOI
10.1016/j.eururo.2026.10.014

Why clinicians should know about it

  • Picked for Oncology and Radiation Oncology (paper of the day, 18 November 2026): Meta-analysis of RCTs, IO benefit in RCC
  • Picked for Urology (paper of the day, 17 November 2026): Randomized-trial meta-analysis informs first-line metastatic renal cancer therapy

Abstract

BACKGROUND AND OBJECTIVE: To quantify heterogeneity in the treatment effects of first-line immuno-oncology (IO)-based combination regimens among patients with metastatic clear-cell renal cell carcinoma (RCC) according to prognosis and potential effect modifiers and to assess which patients benefit most. METHODS: Meta-analysis (preregistered in PROSPERO: CRD42023483638) including randomised trials underpinning first-line IO-based regimens recommended in the European Society for Medical Oncology 2024 guidelines using sunitinib as control, with mature overall survival (OS) data available as of November 2023. Individual patient data (IPD) were obtained for two trials and aggregate data for two others. Prognostic stratification was performed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model and, for IPD trials, by the Clinical Prognostic Index in the Checkpoint Inhibitor era (CPI2) model. Effect modification by sex and programmed death-ligand 1 (PD-L1) expression was assessed. OS benefit was summarised as a hazard ratio (HR) and, in IPD, as the difference in restricted mean survival time (dRMST), and was pooled across trials using fixed-effects inverse-variance-weighted models. KEY FINDINGS AND LIMITATIONS: CheckMate-214, CheckMate-9ER, KEYNOTE-426 and CLEAR were included, totalling 3320 patients (IPD for CheckMate-214 and CheckMate-9ER; n = 1747). Among IPD studies, 42%, 32%, and 26% of patients had CPI2 favourable, intermediate, and poor prognosis, respectively. The respective pooled subgroup dRMSTs were 1.21 (95% CI = -0.82 to 3.25), 3.15 (0.50 to 5.81), and 7.36 (4.56 to 10.17) mo. Using all four studies, the pooled HRs for IMDC favourable, intermediate, and poor subgroups were 0.98 (0.81 to 1.19), 0.78 (0.68 to 0.89), and 0.51 (0.40 to 0.65), respectively. PD-L1 expression at 5% significantly modified the treatment effect. CONCLUSIONS AND CLINICAL IMPLICATIONS: IO-based regimens showed highly divergent OS efficacy across prognostic subgroups, with no significant benefit among patients with a favourable prognosis and the strongest benefit in patients with a poor prognosis.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.